Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in heavily pre-treated platinum resistant ovarian cancer (PROC ... more fully ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Immunocore reports third quarter financial results and provides a business updateKIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q ...

BNT327/PM8002 is a bispecific antibody candidate combining Programmed Cell Death Ligand-1 (“PD-L1”) checkpoint inhibition with Vascular Endothelial Growth Factor A ... platinum-resistant ovarian ...

A recent study has developed a novel method to analyze genetic variations in families with a high incidence of breast cancer.

As of September 30, 2024, Zymeworks has repurchased 1,818,530 shares of the Company's common stock for a cost of $20.6 ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

This article presents highlights from a satellite symposium conducted as part of the European Society for Medical Oncology (ESMO ... for ovarian cancer is exciting; however, better understanding of ...

It's important to be familiar with the signs and symptoms and to talk to your doctor if you have any risk factors for the disease. No screening strategy for ovarian cancer has been proven to reduce ...

Experts don’t know if having HPV alone can lead to cancer, or if you have to have another risk factor for it to happen (like being a cigarette smoker). But it causes about 70% of oropharyngeal ...